Publications by authors named "R Goldwater"

Claim this Profile
A
A Phase 1 Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (S315) Against Diphtheria Toxin.
John Z Sullivan-Bólyai, Larry B Allen, Rebecca Cannon, Kenya P Cohane, Elise Dunzo, Ronald Goldwater

J Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans.
Brian Finan, Jonathan D Douros, Ronald Goldwater, Ann Maria Kruse Hansen, Julie B Hjerpsted

Mol Metab· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055.
Xiao-Hong Zhou, Susanne Prothon, Engin Liathdale, Nicola Ferrari, Kebria Hezaveh, Ronald Goldwater

iScience· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity" [Mol Metab 78 (2023) 101801].
Martin Haljeta Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam

Mol Metab· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity.
Martin Haljeta Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam

Mol Metab· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis